This newsletter presents you the following key sessions:
1. PODCAST with prof. Thomas Powles about Keynote-426: Pembrolizumab plus axitinib as a first-line
treatment option for patients with advanced clear cell renal cell carcinoma
2. Durable responses with amivantamab and lazertinib in chemotherapy-naïve patients with EGFR-mutant
NSCLC who relapsed on osimertinib
3. First-line immunotherapy-based therapy prolongs the survival of patients with advanced oesophageal
squamous cell carcinoma
4. Trastuzumab plus endocrine therapy is non-inferior to trastuzumab plus chemotherapy in patients with
metastatic HR-positive/HER2-positive breast cancer
5. Toripalimab plus gemcitabine and cisplatin as novel first-line treatment for recurrent or metastatic
nasopharyngeal carcinoma



